Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 · New England Journal of Medicine · 2,385 citations
https://doi.org/10.1056/nejmoa1813904
I
Ingrid A. Mayer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
632
Papers
32.4K
Citations
73
h-index
173
i10-index
Ingrid A. Mayer is an academic researcher from AstraZeneca (Netherlands). The author has contributed to research in topics: Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies. The author has an h-index of 73, co-authored 538 publications.
ORCID: 0000-0001-8147-335XPapers by this author
worksAdjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
2018 · New England Journal of Medicine · 2,320 citations
https://doi.org/10.1056/nejmoa1804710
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015 · Annual Review of Medicine · 826 citations
https://doi.org/10.1146/annurev-med-062913-051343
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
2019 · New England Journal of Medicine · 815 citations
https://doi.org/10.1056/nejmoa1814213
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
2018 · Nature · 769 citations
https://doi.org/10.1038/nature25475
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
2020 · Annals of Oncology · 570 citations
https://doi.org/10.1016/j.annonc.2020.11.011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat